Pretransplant aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis

Transplantation

Volumn 97, Issue 3, 2014, Pages 351-357

  Luong, Me Linh ^a   Chaparro, Cecilia ^a   Stephenson, Anne ^b   Rotstein, Coleman ^a   Singer, Lianne G ^a   Waters, Valerie ^c   Azad, Sassan ^a   Keshavjee, Shaf ^b   Tullis, Elizabeth ^b,d   Husain, Shahid ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Aspergillosis; Aspergillus; Cystic fibrosis; Lung transplantation

Indexed keywords

ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INVASIVE PULMONARY ASPERGILLOSIS; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SPUTUM; TIME FACTORS;

EID: 84894094805     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437434.42851.d4     Document Type: Article

References (22)

1. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosisVa review. Med Mycol 2009; 47: 387.
2. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299.
3. Milla CE, Wielinski CL, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 6.
4. Amin R, Dupuis A, Aaron SD, et al. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137: 171.
5. Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16: 598.
6. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosisVstate of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 3(37 Suppl): S225.
7. Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915.
8. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160.
9. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005; 1(43 Suppl): S267.
10. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26: 879.
11. Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114: 1321.
12. Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800.
13. Paradowski LJ. Saprophytic fungal infections and lung transplantationVrevisited. J Heart Lung Transplant 1997; 16: 524.
14. Liu M, Worley S, Mallory GB Jr, et al. Fungal infections in pediatric lung transplant recipients: colonization and invasive disease. J Heart Lung Transplant 2009; 28: 1226.
15. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903.
16. Hadjiliadis D, Sporn TA, Perfect JR, et al. Outcome of lung transplantation in patients with mycetomas. Chest 2002; 121: 128.
17. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195.
18. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepato-toxicity and effectiveness. Am J Transplant 2009; 9: 2085.
19. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
20. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627.
21. Tofte N, Jensen C, Tvede M, et al. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012; 44: 835.
22. Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients? Curr Opin Infect Dis 2013; 26: 317.